Rare neurogenetic diseases with paramagnetic material accumulation in the brain: A case series study

Murat Yilmaz 1 * , Siddika Halicioglu 2, Sule Aydin Turkoglu 1, Serpil Yildiz 1
More Detail
1 Department of Neurology, Bolu Abant İzzet Baysal University, Bolu, Turkey
2 Department of Radiology, Bolu Abant İzzet Baysal University,Bolu, Turkey
* Corresponding Author
J CLIN MED KAZ, Volume 18, Issue 1, pp. 74-78. https://doi.org/10.23950/jcmk/9669
OPEN ACCESS
Download Full Text (PDF)

ABSTRACT

Aim: To draw attention to rare neurogenetic diseases that are characterized by paramagnetic substance accumulation in the brain by sharing 12 subjects who presented with different clinical manifestations.
Material and methods: Twelve patients who presented to our clinic between 2009 and 2019 with different complaints and were diagnosed as having FAHR syndrome, PKAN and Wilson disease were analyzed retrospectively. Presentation symptoms, physical examination findings, radiological and laboratory findings and treatment responses of the patients were evaluated.
Results: Seven of the 12 subjects admitted to our clinic over a 5-year period were female, and 5 were male. The median age at the time of presentation was found to be 31-34 years (21-67). All of the patients received a new diagnosis after presentation. The patients presented with various complaints such as progressive walking difficulties, imbalance, disorder of writing ability, tinnitus, agitation, constant crying, convulsion, frequent falls, speech disorder, and slow movement. In the etiology, 4 of the patients were diagnosed with PKAN, 6 patients were diagnosed with FAHR syndrome and 2 patients were diagnosed with isolated neurological symptoms.
Conclusion: Most of the recent developments related to the roles of metals in neurological diseases have arisen from the identification of new genetic diseases. These rare neurogenetic diseases, which can be manifested with many different clinical features ranging from pyramidal and extrapyramidal findings to neuropsychiatric findings, should be considered in the differential diagnosis since they often affect the young population and the rates of disability and mortality can be reduced with early diagnosis.

CITATION

Yilmaz M, Halicioglu S, Aydin Turkoglu S, Yildiz S. Rare neurogenetic diseases with paramagnetic material accumulation in the brain: A case series study. J CLIN MED KAZ. 2021;18(1):74-8. https://doi.org/10.23950/jcmk/9669

REFERENCES

  • Bozkurt B, Bulakçı M, Kılıç A, Tatlı B, Alyanak B, Oğuz F, et al. Fahr disease case report. The Journal of the Child. 2011; 11(2):90-3. https://doi.org/10.5222/j.child.2011.090
  • Yoshikawa H, Abe T. Transient parkinsonism in bilateral striopallidodentate calcinosis. Pediatr Neurol. 2003; 29(1):75-7. https://doi.org/10.1016/S0887-8994(03)00049-3
  • Aygün D, Terzi M, Güngör L, Ionar M. “Tiger's Eye Sign” in Multiple Sclerosis: A Case Report. Journal of Parkinson's Disease and Movement Disorders. 2011; 14(1):17-20.
  • Işık U, Akgün Y, Peker S, Özek M. Deep Brain Stimulation in Pantothenate Kinase-Related Neurodegeneration (PKAN) Dystonia. Acıbadem University Journal of Health Sciences. 2012; 3(1).
  • Per H, Bayram A. Dystonia in Childhood. Turkey Clinical J Pediatr Sci. 2017; 13(2).
  • Öztürk A, Tüstü R, Özben S. Wilson Disease with Cases: Diagnosis and Treatment; Parkinson Disease. Move Disorders Journal. 2006; 9(2):118-24.
  • Gregory A, Hayflick SJ. Neurodegeneration with brain iron accumulation. Folia neuropathologica/Association of Polish Neuropathologists and Medical Research Centre, Polish Academy of Sciences. 2005; 43(4):286.
  • Hogarth P, Kurian MA, Gregory A, Csányi B, Zagustin T, Kmiec T, et al. Consensus clinical management guideline for pantothenate kinase-associated neurodegeneration (PKAN). Mol Genet Metab. 2017; 120(3):278-87. https://doi.org/10.1016/j.ymgme.2016.11.004
  • Swaiman KF. Hallervorden-Spatz syndrome and brain iron metabolism. Arch Neurol. 1991; 48(12):1285-93. https://doi.org/10.1001/archneur.1991.00530240091029
  • Patil DD, Pujalwar S, Singh Y. HALLERVORDEN SPATZ DISEASE. Journal of Evolution of Medical and Dental Sciences. 2018; 7(52):5570-3.
  • Hundallah K, Al Hakeem A. Pantothenate kinase-associated neurodegeneration. Neurosciences. 2017; 22(2):156. https://doi.org/10.17712/nsj.2017.2.20170197
  • Zhou B, Westaway SK, Levinson B, Johnson MA, Gitschier J, Hayflick SJ. A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. Nat Genet. 2001; 28(4):345-9. https://doi.org/10.1038/ng572
  • Amisha F, Munakomi S. Fahr Syndrome. StatPearls [Internet]. 2020.
  • Kobayashi S, Yamadori I, Miki H, Ohmori M. Idiopathic nonarteriosclerotic cerebral calcification (Fahr's disease): an electron microscopic study. Acta Neuropathol. 1987; 73(1):62-6. https://doi.org/10.1007/BF00695503
  • Saleem S, Aslam HM, Anwar M, Anwar S, Saleem M, Saleem A, et al. Fahr’s syndrome: literature review of current evidence. Orphanet Journal of Rare Diseases. 2013; 8(1):1-9. https://doi.org/10.1186/1750-1172-8-156
  • Kaçar E. Nadir görülen bir intrakranial kalsifikasyon olgusu: FAHR sendromu. Kocatepe Tıp Dergisi. 2010; 11(1):31-3.
  • Baba Y, Broderick DF, Uitti RJ, Hutton ML, Wszolek ZK, editors. Heredofamilial brain calcinosis syndrome. Mayo Clin Proc; 2005: Elsevier. https://doi.org/10.4065/80.5.641
  • Jaworski K, Styczyńska M, Mandecka M, Walecki J, Kosior DA. Fahr syndrome–an important piece of a puzzle in the differential diagnosis of many diseases. Polish Journal of Radiology. 2017; 82:490. https://doi.org/10.12659/PJR.902024
  • Demİrcan F, Gözel N, Kilinç F, Göya C. Konvülsiyon ile Başvuran Fahr Sendromu: Olgu Sunumu. Firat Tip Dergisi. 2014; 19(4).
  • Hanagu F, Hanagu H. Wilson's Disease. Turkish Journal of Neurology 2013; 19:122-7. https://doi.org/10.4274/Tnd.60566
  • Shanmugavel KP, Kumar R, Li Y, Wittung-Stafshede P. Wilson disease missense mutations in ATP7B affect metal-binding domain structural dynamics. Biometals. 2019; 32(6):875-85. https://doi.org/10.1007/s10534-019-00219-y
  • Da Costa CM, Baldwin D, Portmann B, Lolin Y, Mowat AP, Mieli‐Vergani G. Value of urinary copper excretion after penicillamine challenge in the diagnosis of Wilson's disease. Hepatology. 1992; 15(4):609-15. https://doi.org/10.1002/hep.1840150410
  • Bandmann O, Weiss KH, Kaler SG. Wilson's disease and other neurological copper disorders. The Lancet Neurology. 2015; 14(1):103-13. https://doi.org/10.1016/S1474-4422(14)70190-5
  • Kuloğlu Z, Gİrgİn N. Wilson Hastalığı. Türkiye Klinikleri Pediatri Dergisi. 2004; 13(4):246-53.